Novartis Financial Results - Q1 2026
Novartis announces the company’s financial results for the first quarter of 2026.
Latest news
Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
Manufacturing expansion in the United States
Novartis is expanding our manufacturing and R&D facilities in the US to scale innovation, help patients and create jobs.
Bringing breakthroughs to more patients
At Novartis, we don’t just discover life-changing medicines, we're part of a broader effort to help ensure medicines reach the people who need them most, wherever they live, because the true value of innovation lies in its ability to improve lives.
Annual reporting suite
Explore and download our Annual Report 2025, Report on Nonfinancial Matters 2025 and other reporting documents.